Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients

Pharmacogenomics Journal

Volumn 13, Issue 6, 2013, Pages 484-489

  Habtewold, A ^a,b   Amogne, W ^a,b   Makonnen, E ^b   Yimer, G ^a,b   Nylen H ^a   Riedel, K D ^c   Aderaye, G ^b   Bertilsson, L ^a   Burhenne, J ^c   Diczfalusy, U ^a   Aklillu, E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

4b hydroxycholesterol; cholesterol; CYP2B6; efavirenz; Ethiopians; induction

Indexed keywords

4BETA HYDROXYCHOLESTEROL; ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; CHOLESTEROL DERIVATIVE; CYTOCHROME P450 2B6; CYTOCHROME P450 3A; CYTOCHROME P450 3A5; EFAVIRENZ; GLUCURONOSYLTRANSFERASE 2B7; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN 1; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG BLOOD LEVEL; ENZYME INDUCTION; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY;

BENZOXAZINES; CYTOCHROME P-450 CYP3A; ENZYME INDUCTION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84888131126     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.46     Document Type: Article

References (30)

1. Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002; 72: 1-9.
2. Josephson F, Bertilsson L, Bottiger Y, Flamholc L, Gisslen M, Ormaasen V et al. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4b-Hydroxycholesterol levels. Eur J Clin Pharmacol 2008; 64: 775-781.
3. Kanebratt KP, Diczfalusy U, Backstrom T, Sparve E, Bredberg E, Bottiger Y et al. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther 2008; 84: 589-594.
4. Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Bottiger Y, Bertilsson L. 4bhydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol 2009; 67: 38-43.
5. Lutjohann D, Marinova M, Schneider B, Oldenburg J, von Bergmann K, Bieber T et al. 4b-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo-effects of itraconazole in man. Int J Clin Pharmacol Ther 2009; 47: 709-715.
6. Mukonzo JK, Nanzigu S, Rekic D, Waako P, Roshammar D, Ashton M et al. HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. Clin Pharmacokinet 2011; 50: 531-540.
7. Mukonzo JK, Roshammar D, Waako P, Andersson M, Fukasawa T, Milani L et al. A novel polymorphism in ABCB1 gene, CYP2B6 6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 2009; 68: 690-699.
8. Mahungu TW, Nair D, Smith CJ, Egan D, Youle M, Johnson MA et al. The relationships of ABCB1 3435C4T and CYP2B6 516G4T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz. Clin Pharmacol Ther 2009; 86: 204-211.
9. Burger D, van der Heiden I, la Porte C, van der Ende M, Groeneveld P, Richter C et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 2006; 61: 148-154.
10. Habtewold A, Amogne W, Makonnen E, Yimer G, Riedel KD, Ueda N et al. Longterm effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother 2011; 66: 2350-2361.
11. Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, Suda A et al. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther 2011; 90: 406-413.
12. Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, Suda A et al. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 2010; 88: 676-684.
13. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 2005; 39: 307-312.
14. Michaud V, Ogburn E, Thong N, Aregbe AO, Quigg TC, Flockhart DA et al. Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. Clin Pharmacol Ther 2012; 91: 475-482.
15. van Luin M, Van der Ende ME, Richter C, Visser M, Faraj D, Van der Ven A et al. Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ ritonavir or atazanavir/ritonavir. AIDS 2010; 24: 1223-1226.
16. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broome U, Einarsson C et al. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem 2001; 276: 38685-38689.
17. Diczfalusy U, Nylen H, Elander P, Bertilsson L. 4b-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol 2011; 71: 183-189.
18. Wide K, Larsson H, Bertilsson L, Diczfalusy U. Time course of the increase in 4betahydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. Br J Clin Pharmacol 2008; 65: 708-715.
19. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306: 287-300.
20. Kwara A, Lartey M, Sagoe KW, Court MH. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS 2011; 25: 388-390.
21. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 819-850.
22. Faucette SR, Sueyoshi T, Smith CM, Negishi M, Lecluyse EL, Wang H. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J Pharmacol Exp Ther 2006; 317: 1200-1209.
23. Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007; 320: 72-80.
24. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004; 44: 1273-1281.
25. Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, Suda A et al. High plasma efavirenz level and CYP2B66 are associated with efavirenzbased HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J; advance online publication, 23 August 2011; doi:10. 1038/tpj. 2011. 34.
26. Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS ONE 2011; 6: e27810.
27. Byakika-Kibwika P, Lamorde M, Mayito J, Nabukeera L, Namakula R, Mayanja-Kizza H et al. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 2012; 67: 2213-2221.
28. Gebeyehu E, Engidawork E, Bijnsdorp A, Aminy A, Diczfalusy U, Aklillu E. Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. Pharmacogenomics J 2011; 11: 130-137.
29. Mukonzo JK, Waako P, Ogwal-Okeng J, Gustafsson LL, Aklillu E. Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans. Ther Drug Monit 2010; 32: 346-352.
30. Jetter A, Fatkenheuer G, Frank D, Klaassen T, Seeringer A, Doroshyenko O et al. Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? Antivir Ther 2010; 15: 975-983.